[144] GENPACT LIMITED SEC Filing

Rhea-AI Filing Summary

Genpact Limited (G) notice: an individual who received 2,695 restricted common shares from the issuer on 08/31/2025 intends to sell those shares on or about 09/03/2025. The filer lists Morgan Stanley Smith Barney LLC as the broker and values the shares' aggregate market value at $120,641.68 based on outstanding common shares of 174,270,076. The filing reports no other sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

• Complete Rule 144 details provided: class, broker, number of shares, aggregate market value, outstanding shares, and approximate sale date are all disclosed
• Transaction originates from restricted stock issued by the issuer, with acquisition and payment information stated
• No other sales in past three months, indicating this is an isolated proposed sale

Negative

• None.

Insights

Securities Analyst

TL;DR: Small insider sale of newly issued restricted shares; immaterial to company-wide capitalization but useful for disclosure tracking.

The notice shows a proposed sale of 2,695 restricted shares, representing a de minimis fraction of 174,270,076 shares outstanding (well under 0.01%). The use of a major broker and the presence of a specified aggregate market value provide clear execution details. No prior sales in the past three months are reported, which indicates this is an isolated disposal of restricted stock rather than part of ongoing trading activity.

Corporate Governance Expert

TL;DR: Proper Rule 144 notice filed for restricted stock sale; disclosure aligns with routine insider compliance practices.

The filer disclosed acquisition date, nature of grant (restricted stock), and planned sale date, satisfying Rule 144 reporting elements. The seller affirms absence of undisclosed material adverse information, a standard legal representation. This filing does not indicate governance or control changes and contains no material items affecting shareholder governance or board composition.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2695	120641.68	174270076	09/03/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/31/2025	Restricted Stock	Issuer			2695	08/31/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Genpact Limited (G) disclose?

The form discloses a proposed sale of 2,695 restricted common shares, acquired on 08/31/2025, with an approximate sale date of 09/03/2025 and aggregate market value of $120,641.68.

Who is the broker handling the proposed sale in the Genpact (G) Form 144?

The broker listed is Morgan Stanley Smith Barney LLC located at 1 New York Plaza, 8th Floor, New York, NY.

Does the Form 144 report any other sales by the seller in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

What type of acquisition is indicated for the shares in the filing?

The shares were acquired as Restricted Stock from the issuer, with payment and acquisition both dated 08/31/2025.

How significant is the proposed sale relative to Genpact’s outstanding shares?

The proposed sale of 2,695 shares is negligible relative to 174,270,076 shares outstanding (well under 0.01%).